[Trastuzumab in combination with chemotherapy versus chemotherapy alone for first-line treatment of HER2-positive advanced gastric or gastroesophageal junction cancer: a Phase III, multi-center, randomized controlled trial, Chinese subreport].

@article{Shen2013TrastuzumabIC,
  title={[Trastuzumab in combination with chemotherapy versus chemotherapy alone for first-line treatment of HER2-positive advanced gastric or gastroesophageal junction cancer: a Phase III, multi-center, randomized controlled trial, Chinese subreport].},
  author={Lin Shen and Jianming Xu and Feng-yi Feng and Shunchang Jiao and Liwei Wang and Jin Li and Zhong-zhen Guan and Shukui Qin and Jie-jun Wang and Shi-ying Yu and Yajie Wang and Ye-ning Jin and Min Tao and Lei-zhen Zheng and Liang-xi Pan},
  journal={Zhonghua zhong liu za zhi [Chinese journal of oncology]},
  year={2013},
  volume={35 4},
  pages={295-300}
}
OBJECTIVE To evaluate the efficacy and safety of trastuzumab in combination with chemotherapy versus chemotherapy alone in the first-line treatment of HER-2-positive advanced gastric or gastro-oesophageal junction cancer. METHODS Fifteen Chinese research centers are involved in the BO18255 (ToGA) study. Patients with gastric or gastro-oesophageal junction cancer were eligible for inclusion if their tumor showed overexpression of HER-2 protein by immunohistochemistry +++ or FISH-positive… CONTINUE READING
Highly Cited
This paper has 18 citations. REVIEW CITATIONS

Citations

Publications citing this paper.
Showing 1-7 of 7 extracted citations

Similar Papers

Loading similar papers…